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Introduction
Mismatch repair (MMR) is a DNA repair
pathway implicated in many solid tumors
including endometrial cancer (EC). It is
currently standard of care to test for
mismatch repair deficiencies (MMRd) on
endometrial cancer pathology after
staging hysterectomy. It is well shown
that EC disproportionately affects Black
women, but we do not yet know if these
same findings of MMRd have an equal
prognostic value in the Black EC
population as has been shown in their
White counterparts, as most studies
include small subsets of Black patients.
Thus, we sought to describe the impact of
MMRd in a large and racially diverse
Southern EC population and to identify
whether differences in recurrence free
and overall survival based on race as well
as type of MMR deficiency was found.

Methods

Recurrence Free Survival (RFS) between Black and White
patients was not significantly different, but Black patients
tended to have a higher probability of recurrence at 1 and 2
years when compared to non-Black patients 21% vs 10%
and 38% vs 24%, respectively, p=0.1.
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A retrospective cohort of EC patients
receiving care within a large urban
healthcare system encompassing both
academic and community hospitals was
performed. Electronic medical records
were reviewed, and data collected via
RedCap. Variables of interest included
basic patient demographic,
clinicopathologic as well as molecular
testing. Specifically, EC stage, histology,
MMR testing, and genetic testing were
compared to patient geographic,
demographic, treatment, and outcome
data.
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Based on our study of
an ethnically and
racially diverse EC
population, race was
not associated with
incidence of MMRd.
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N=127 patients were included. Of those, n=55,
(43.7%), identified as Black, n=60, (47.6%), as
White, and the remainder n=12, (8.7%), as Other or
unknown. A total of n=25, (20%), patients had
MMRd, 11, (44%), being of Black race and 14,
(56%), of White race, p=0.379. Patients with MMRd
tended to be younger than those with MMR
proficient (MMRp), mean age 59 vs 61 years
respectively, p=0.212. Time to recurrence was longer
for MMRd patients compared to MMRp patients,
22.7 months vs 9.6 months, p=0.352. For all
patients, recurrence free survival (RFS) between
Black and White patients was not significantly
different, but Black patients tended to have a higher
probability of recurrence at 1 and 2 years when
compared to non-Black patients 21% vs 10% and
38% vs 24%, respectively, p=0.1. In the 25 patients
that had MMRd, 11 were African American, of
which 1 patient died without experiencing a
recurrence and 2 patients had a recurrence and died,
whereas no non-Black patients with MMRd
experienced recurrence or death.

Conclusions
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These findings highlight the need to better characterize
the differential impact that race contributes on MMR
status and its implications related to survival. This will
aid oncologist in counseling on treatment, prognosis
and recurrence risk as we already know Black race is a
negative risk factor in EC outcomes. Furthermore, in
this cohort, all recurrences and deaths in patients with
MMRd were found in the Black patients. However,
due to low numbers of MMRd patients overall, we
were not able to conclude on the differing prognostic
recurrence free survival by race. These trends,
however, do confirm the importance of inclusion and
representation of highly burdened populations to better
understand the potentially varying prognostic features
of MMRd across race and ethnicity.
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